Tumors contain multiple distinct subclonal populations that vary across different spatial regions and accumulate over time. Understanding the longitudinal and spatial dynamics of these subclones is necessary for comprehending tumor biology and progression. [@hiley_deciphering_2014]
Definitions
Synthesis
Tumors are established as complex ecosystems harboring multiple genetically distinct subclones that vary both across spatial locations within the tumor mass and through time during tumor evolution. This heterogeneity arises mechanistically from processes like chromosomal instability, which simultaneously generates diverse genomic alterations and creates selective pressures that shape subclonal architecture, as seen in aneuploid tumors that consistently inactivate Stat1 signaling to evade immune surveillance triggered by their genomic chaos. The spatial and temporal distribution of driver mutations across these subclones directly determines critical clinical outcomes including therapy response and evolutionary trajectories, while also producing variable transcriptional programs such as hypoxia responses that differ between cells experiencing distinct microenvironmental niches. What remains less resolved is how the balance between diversifying forces like chromosomal instability and converging selective pressures like immune evasion ultimately determines which subclones dominate at different tumor sites and timepoints, and whether the mechanistic conservation of certain adaptations like Stat1 inactivation represents a limited repertoire of viable evolutionary solutions or simply the most commonly selected among many possible paths.
Related
- Stat1 inactivation mechanism is conserved between mouse and human aneuploid cancers
- Chromosomal instability promotes immune cell infiltration into tumors
- Subclonal driver events determine therapy response and tumor evolution
- Hypoxia-related transcriptional programs are variably expressed in glioblastoma cells
- Aneuploid cancers inactivate Stat1 to circumvent immune surveillance
- Aneuploid tumors inactivate Stat1 signaling with increased Myc activity
- p53 loss is common but not enriched in chromosomally unstable tumors